Amsterdam

• A study looking at how effective and safe AZD7798 is in people with Crohn's disease Ended recruitment
  2023-510487-12-00 4 2024-11-29 Crohn's Disease
• Prevention of the return of nephrotic syndrom in children by adding levamisole to prednisolone treatment Ended recruitment
  2024-517467-23-00 5 2024-11-29 steroid sensitive idiopathic nephrotic syndrome
• Trial Examining Methods for Antidepressant Discontinuation (TEMPO) Ended recruitment
  2024-511997-66-00 6 2024-11-22 Major Depressive Disorder
• Study of JDQ443 in advanced cancer with a specific mutation (G12C) of the KRAS gene Ended recruitment
  2023-508073-87-00 7 2024-11-14 Advance solid tumors harboring the KRAS G12C mutation
• A Patient guided dose reduction strategy of tyrosine kinase inhibitors in chronic myeloid leukaemia: RODEO study Ended recruitment
  2024-516511-24-00 11 2024-11-14 Chronic myeloid leukaemia
• GenePHIT: A study to learn more about how well a new gene therapy (AB-1002) works and its safety in participants with congestive heart failu … Ended recruitment
  2024-510581-17-00 4 2024-11-05 Adult subjects with New York Heart Association (NYHA) Class III conges
• A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended recruitment
  2023-508636-61-00 5 2024-10-24 Crohn’s Disease
• A Phase 2a/b study of the efficacy and safety of subcutaneous amlitelimab in adults with non-responsive celiac disease Ended recruitment
  2024-511213-38-00 4 2024-10-15 Coeliac disease
• A phase 1b-2 study of mitomycin-C / capecitabine chemoradiotherapy combined with ipilumimab and nivolumab or nivolumab monotherapy as bladde … Ended recruitment
  2023-509460-19-00 9 2024-10-11 Muscle Invasive bladder cancer
• Intravenous immunoglobulin and prednisone vs. prednisone in newly diagnosed myositis: a double blind randomized clinical trial Ended recruitment
  2024-516057-42-00 4 2024-10-10 Idiopathic inflammatory myopathy
• Long-term Follow-up Study of Male Adults with Hemophilia B Previously Treated with Etranacogene Dezaparvovec (CSL222) Ended recruitment
  2023-503765-37-00 10 2024-09-30 Hemophilia B
• A Phase 1/2 Study of MK-2870 plus EV plus Pembrolizumab in la/mUC Ended recruitment
  2023-506387-14-00 7 2024-09-24 Advanced Urothelial Carcinoma
• A study to determine if ravulizumab can help preserve kidney function in adults with immunoglobulin A nephropathy (IgAN) Ended recruitment
  2023-507851-31-00 5 2024-09-23 Immunoglobulin A Nephropathy (IgAN)
• AMG 193 in Combination with Other Therapies in Subjects with Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous … Ended recruitment
  2024-511195-33-00 3 2024-09-23 Gastrointestinal tract, biliary tract, or pancreatic cancers with homo
• First line treatment with VeNEtoclaX and ibruTinib induction followed by obinutuzumab intenSificaTion Exclusively in CLL/SLL Patients not in … Ended recruitment
  2022-502808-72-00 4 2024-09-11 Chronic Lymphocytic Leukemia
• Safe Stop ipi-nivo Ended recruitment
  2024-516938-34-00 5 2024-09-11 Melanoma
• A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended recruitment
  2023-509190-23-00 5 2024-09-03 Atherosclerotic Cardiovascular Disease Elevated lp(a)
• A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Capsules Compared to Intravenously (IV) Infused Rituximab Plus IV Infu … Ended recruitment
  2024-510965-41-00 5 2024-09-03 Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
• MLS-101-901: An Open-Label Extension Study to Assess the Long-Term Safety, Efficacy, and Tolerability of Lorundrostat in Subjects with Hyper … Ended recruitment
  2023-508670-28-00 5 2024-08-26 Hypertension
• Extension trial for adults with high cholesterol who completed a MK-0616 clinical trial Ended recruitment
  2023-504922-20-00 5 2024-08-23 Hypercholesterolemia
• Rivaroxaban Monotherapy and CYP2C19 Genotype Testing in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention Ended recruitment
  2023-508904-39-00 6 2024-08-22 Coronary artery disease
• Phase I/II study of ANV600 single agent or in combination with pembrolizumab in participants with advanced solid tumors (EXPAND-1) Ended recruitment
  2023-509633-39-00 7 2024-08-06 Advanced solid tumours
• MAD Ended recruitment
  2024-516379-34-00 6 2024-08-02 Myopia
• ARTEMIS - A research study to look at how ziltivekimab works compared to placebo in people who have had a heart attack Ended recruitment
  2023-506876-28-00 5 2024-08-01 The medical condition we are investigating is type 1 AMI (STEMI and NS

Showing 649–672 of 1,112 trials